PKC agonism restricts innate immune suppression, promotes antigen cross-presentation and synergizes with agonistic CD40 antibody therapy to activate CD8+ T cells in breast cancer. (10th April 2022)

• Record Type: Journal Article
• Authors: Chaib, Mehdi; Sipe, Laura M.; Yarbro, Johnathan R.; Bohm, Margaret S.; Counts, Brittany R.; Tanveer, Ubaid; Pingili, Ajeeth K.; Daria, Deidre; Marion, Tony N.; Carson, James A.; Thomas, Paul G.; Makowski, Liza
• Is Part Of: Cancer letters. Volume 531(2022)
• Page Start: 98
• Page End: 108
• Publication Date: 2022-04-10
• Subjects: MDSC -- DC -- Cross-presentation -- CD40 -- PKC; Cancer -- Periodicals; Neoplasms -- Periodicals; Cancer -- Périodiques; Electronic journals; 616.994
• DOI: 10.1016/j.canlet.2022.01.017
• Languages: English
• ISSNs: 0304-3835

Abstract

Abstract: Myeloid-derived suppressor cells (MDSCs) are an immature innate cell population that expands in pathological conditions such as cancer and suppresses T cells via production of immunosuppressive factors. Conversely, efficient cytotoxic T cell priming is dependent on the ability of antigen-presenting cells (APCs) to cross-present tumor antigens to CD8 + T cells, a process that requires a specific subtype of dendritic cells (DCs) called conventional DC1 (cDC1) which are often dysfunctional in cancer. One way to activate cDC1 is ligation of CD40 which is abundantly expressed by myeloid cells and its agonism leads to myeloid cell activation. Thus, targeting MDSCs while simultaneously expanding cross-presenting DCs represents a promising strategy that, when combined with agonistic CD40, may result in long-lasting protective immunity. In this study, we investigated the effect of PKC agonists PEP005 and prostratin on MDSC expansion, differentiation, and recruitment to the tumor microenvironment. Our findings demonstrate that PKC agonists decreased MDSC expansion from hematopoietic progenitors and induced M-MDSC differentiation to an APC-like phenotype that expresses cDC1-related markers via activation of the p38 mitogen-activated protein kinase (MAPK) pathway. Simultaneously, PKC agonists favored cDC1 expansion at the expense of cDC2 and plasmacytoid DCs (pDC). Functionally, PKC agonists blunted MDSC suppressive activity and enhanced MDSC cross-priming capacity both in vitro and in vivo . Finally, combination of PKC agonism with agonistic CD40 mAb resulted in a marked reduction in tumor growth with a significant increase in intratumoral activated CD8 + T cells and tissue-resident memory CD8 + T cells in a syngeneic breast cancer mouse model. In sum, this work proposes a novel promising strategy to simultaneously target MDSCs and promote APC function that may have highly impactful clinical relevance in cancer patients. Graphical abstract: Overview figure: PKC agonism decreases MDSC and increases cDC1 expansion from the bone marrow, induces M-MDSC differentiation to CD103 + DC-like cells that can cross-prime CD8 + T cells, and synergizes with agonistic CD40 mAb therapy to increase intratumoral activated CD8 + T cells, thus resulting in blunting of tumor growth. Image 1 Highlights: PKC agonism suppresses murine breast cancer tumor growth in vivo. PKC agonism impairs MDSC expansion, trafficking, and suppressive capacity and favors cDC1 expansion. PKC agonism induces M-MDSC differentiation to cross-presenting DC-like cells via activation of the p38 MAPK pathway. Combination of PKC agonism and agonistic CD40 synergistically promotes activation of intratumoral CD8 + T cells and tissue-resident memory CD8 + T cells (Trm) in vivo.